Renaissance Technologies LLC raised its position in shares of Aptevo Therapeutics Inc (NASDAQ:APVO) by 11.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,277,100 shares of the biotechnology company’s stock after acquiring an additional 127,700 shares during the period. Renaissance Technologies LLC owned approximately 0.06% of Aptevo Therapeutics worth $6,488,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently modified their holdings of the company. Northern Trust Corp raised its holdings in shares of Aptevo Therapeutics by 21.2% during the 2nd quarter. Northern Trust Corp now owns 70,416 shares of the biotechnology company’s stock worth $352,000 after acquiring an additional 12,299 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Aptevo Therapeutics by 5.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,425,567 shares of the biotechnology company’s stock worth $7,242,000 after acquiring an additional 73,911 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Aptevo Therapeutics by 20.2% during the 3rd quarter. Acadian Asset Management LLC now owns 441,765 shares of the biotechnology company’s stock worth $2,244,000 after acquiring an additional 74,256 shares in the last quarter. 32.77% of the stock is currently owned by institutional investors and hedge funds.
Several analysts recently weighed in on the company. Zacks Investment Research lowered Aptevo Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 15th. LADENBURG THALM/SH SH assumed coverage on Aptevo Therapeutics in a report on Monday, November 5th. They set a “buy” rating and a $14.00 price target on the stock. Finally, Roth Capital set a $12.00 price target on Aptevo Therapeutics and gave the company a “buy” rating in a report on Thursday, November 15th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Aptevo Therapeutics presently has an average rating of “Buy” and a consensus target price of $10.69.
NASDAQ:APVO opened at $1.59 on Friday. Aptevo Therapeutics Inc has a fifty-two week low of $1.11 and a fifty-two week high of $6.35. The firm has a market cap of $36.72 million, a P/E ratio of -1.04 and a beta of 3.00. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.65 and a current ratio of 3.91.
Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Wednesday, November 14th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.01. Aptevo Therapeutics had a negative return on equity of 78.85% and a negative net margin of 252.44%. The company had revenue of $5.82 million for the quarter, compared to analyst estimates of $6.87 million. Sell-side analysts forecast that Aptevo Therapeutics Inc will post -2.31 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was first published by Macon Daily and is the sole property of of Macon Daily. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://macondaily.com/2019/01/12/renaissance-technologies-llc-purchases-127700-shares-of-aptevo-therapeutics-inc-apvo.html.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Recommended Story: Understanding Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding APVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aptevo Therapeutics Inc (NASDAQ:APVO).
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.